| Discovery, synthesis, and in vivo activity of a new class of pyrazoloquinazolines as selective inhibitors of aurora B kinase AA Mortlock, KM Foote, NM Heron, FH Jung, G Pasquet, JJM Lohmann, ... Journal of medicinal chemistry 50 (9), 2213-2224, 2007 | 315 | 2007 |
| AZD9496: An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ER-Positive and ESR1-Mutant Breast Tumors in Preclinical Models HM Weir, RH Bradbury, M Lawson, AA Rabow, D Buttar, RJ Callis, ... Cancer research 76 (11), 3307-3318, 2016 | 209 | 2016 |
| Optimization of a Novel Binding Motif to (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl … C De Savi, RH Bradbury, AA Rabow, RA Norman, C de Almeida, ... Journal of medicinal chemistry 58 (20), 8128-8140, 2015 | 181 | 2015 |
| Total synthesis of the microtubule-stabilizing agent (−)-laulimalide I Paterson, C De Savi, M Tudge Organic Letters 3 (20), 3149-3152, 2001 | 164 | 2001 |
| Discovery of novel and potent thiazoloquinazolines as selective Aurora A and B kinase inhibitors FH Jung, G Pasquet, C Lambert-van der Brempt, JJM Lohmann, N Warin, ... Journal of medicinal chemistry 49 (3), 955-970, 2006 | 121 | 2006 |
| Quest for a COVID-19 cure by repurposing small-molecule drugs: mechanism of action, clinical development, synthesis at scale, and outlook for supply C De Savi, DL Hughes, L Kvaerno Organic Process Research & Development 24 (6), 940-976, 2020 | 93 | 2020 |
| Discovery of BLU-945, a reversible, potent, and wild-type-sparing next-generation EGFR mutant inhibitor for treatment-resistant non-small-cell lung cancer MS Eno, JD Brubaker, JE Campbell, C De Savi, TJ Guzi, BD Williams, ... Journal of medicinal chemistry 65 (14), 9662-9677, 2022 | 76 | 2022 |
| Discovery of AZD4573, a potent and selective inhibitor of CDK9 that enables short duration of target engagement for the treatment of hematological malignancies B Barlaam, R Casella, J Cidado, C Cook, C De Savi, A Dishington, ... Journal of Medicinal Chemistry 63 (24), 15564-15590, 2020 | 73 | 2020 |
| 1296P BLU-945, a highly potent and selective 4th generation EGFR TKI for the treatment of EGFR T790M/C797S resistant NSCLC SS Schalm, T Dineen, SM Lim, CW Park, J Hsieh, R Woessner, Z Zhang, ... Annals of Oncology 31, S839, 2020 | 61* | 2020 |
| Synthesis of the Macrocyclic Core of Laulimalide I Paterson, C De Savi, M Tudge Organic Letters 3 (2), 213-216, 2001 | 56 | 2001 |
| Investigation of (E)-3-[4-(2-Oxo-3-aryl-chromen-4-yl)oxyphenyl]acrylic Acids as Oral Selective Estrogen Receptor Down-Regulators SL Degorce, A Bailey, R Callis, C De Savi, R Ducray, G Lamont, ... Journal of Medicinal Chemistry 58 (8), 3522-3533, 2015 | 52 | 2015 |
| Elaboration of the side-chain of amino acid derivatives by palladium catalysed couplings GT Crisp, YL Jiang, PJ Pullman, C De Savi Tetrahedron 53 (51), 17489-17500, 1997 | 41 | 1997 |
| Diastereoselective synthesis of (–)-N-acetylneuraminic acid (Neu5Ac) from a non-carbohydrate source CD Savi Journal of the Chemical Society, Perkin Transactions 1, 2251-2252, 1998 | 34 | 1998 |
| Efficacious inhaled PDE4 inhibitors with low emetic potential and long duration of action for the treatment of COPD C De Savi, RJ Cox, DJ Warner, AR Cook, MR Dickinson, A McDonough, ... Journal of Medicinal Chemistry 57 (11), 4661-4676, 2014 | 32 | 2014 |
| Hydantoin based inhibitors of MMP13—discovery of AZD6605 C De Savi, D Waterson, A Pape, S Lamont, E Hadley, M Mills, KM Page, ... Bioorganic & medicinal chemistry letters 23 (16), 4705-4712, 2013 | 26 | 2013 |
| Selective non zinc binding inhibitors of MMP13. CD Savi, AD Morley, A Ting, I Nash, K Karabelas, CM Wood, M James, ... Bioorganic & medicinal chemistry letters, 2011 | 26 | 2011 |
| The design and synthesis of novel N-hydroxyformamide inhibitors of ADAM-TS4 for the treatment of osteoarthritis C De Savi, A Pape, JG Cumming, A Ting, PD Smith, JN Burrows, M Mills, ... Bioorganic & medicinal chemistry letters 21 (5), 1376-1381, 2011 | 24 | 2011 |
| Chemical compounds C De Savi, R Bradbury, A Rabow, R Norman, D Buttar, C Donald, ... US Patent WO2014/0,357,661, 2014 | 23* | 2014 |
| First total synthesis of (+)-3-deoxy-D-glycero-D-galacto-2-nonulosonic acid (KDN) from a non-carbohydrate source CD Savi Chemical Communications, 1189-1190, 1998 | 20 | 1998 |
| Orally active achiral N-hydroxyformamide inhibitors of ADAM-TS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) for the treatment of osteoarthritis C De Savi, A Pape, Y Sawyer, D Milne, C Davies, JG Cumming, A Ting, ... Bioorganic & medicinal chemistry letters 21 (11), 3301-3306, 2011 | 18 | 2011 |
Richard A. NormanManaging Director, Norman ConsultingVerified email at normanconsulting.no
